Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03645928 · ClinicalTrials.gov registry record · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT03645928 is a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 245 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03645928, a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Ipilimumab
- BIOLOGICAL LN-145
- BIOLOGICAL Lifileucel
- BIOLOGICAL LN-145-S1
Study Locations (20)
California
- University of California, San Diego - La Jolla
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
Florida
- Mount Sinai Medical Center - Miami Beach
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health System - Detroit
New Jersey
- MD Anderson at Cooper - Camden
- Morristown Medical Center - Morristown
New York
- Columbia University - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University - Columbus
Colorado
- University of Colorado - Denver
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2029-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03645928
The ClinicalTrials.gov registry entry for NCT03645928 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03645928 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03645928 about?
NCT03645928 is a clinical study titled "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors". A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
What is the current status of trial NCT03645928?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2019-05-07. Estimated completion is 2029-08-09.
What conditions does trial NCT03645928 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT03645928?
The interventions under investigation include: Pembrolizumab (DRUG), Ipilimumab (DRUG), LN-145 (BIOLOGICAL), Lifileucel (BIOLOGICAL), LN-145-S1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03645928?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03645928 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.